Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilotrif Approval Gives Boehringer Milestone, But Can It Compete With Tarceva?

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approval of its first oncology drug is a victory for Boehringer Ingelheim. Now comes another challenge – a commercial battle with Roche’s Tarceva, which is firmly established across lines of therapy for EGFR-positive lung cancer patients.

You may also be interested in...



Boehringer Joins Next Generation Via Hanmi EGFR Inhibitor Deal

Hanmi’s third-generation EGFR inhibitor HM61713, acquired for $50 million up front, strongly complements Boehringer’s Gilotrif/Giotrif, but the new asset is far behind competitors from AstraZeneca and Clovis.

Broader Indications For Tarceva As Astellas Scales Back In The U.S.

The Japanese pharma is consolidating its U.S. operations, including the shuttering of OSI, where Tarceva initially was developed, as the cancer drug gains another indication with a companion diagnostic.

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075954

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel